首页> 外国专利> METHOD FOR PREDICTING THE EFFECTIVENESS OF THE TARGETED THERAPY WITH CETUXIMAB IN THE PATIENTS SUFFERING SQUAMOUS CELL CARCINOMA OF THE TONGUE AND ORAL MUCOSA

METHOD FOR PREDICTING THE EFFECTIVENESS OF THE TARGETED THERAPY WITH CETUXIMAB IN THE PATIENTS SUFFERING SQUAMOUS CELL CARCINOMA OF THE TONGUE AND ORAL MUCOSA

机译:舌头鳞癌和口腔粘膜癌患者中西妥昔单抗靶向治疗的疗效预测方法

摘要

FIELD: medicine.;SUBSTANCE: invention refers to medicine, namely to oncology, and can be used to predict the effectiveness of the targeted therapy with cetuximab in the patients with squamous cell carcinoma of the tongue and the oral mucosa. Tumor tissue is examined. After the second course of polychemotherapeutic treatment with inclusion of target therapy of cetuximab in patient with squamous carcinoma of tongue and oral mucosa, tumor trepan biopsy is conducted. In the obtained tumor sample, the level of growth factors VEGF-A and TGF-β, calculating the ratio of VEGF-A/TGF-β. At value of this ratio ≥0.850 high efficiency of cetuximab therapy is predicted. If its value ≤0.384 predict low effectiveness of cetuximab therapy. Values between said intervals are considered to be undefined.;EFFECT: method provides determining the effectiveness of the targeted therapy with cetuximab in the patients with squamous cell and oral mucosa by examining the content of the growth factors VEGF-A and TGF-β in tumor tissue at the stage of polychemotherapeutic treatment – after the second course of polychemotherapy with inclusion of cetuximab.;1 cl, 2 ex
机译:技术领域本发明涉及医学,即肿瘤学,并且可用于预测西妥昔单抗靶向治疗在舌鳞状细胞癌和口腔粘膜患者中的有效性。检查肿瘤组织。在对舌鳞状癌和口腔粘膜癌患者进行第二次多化学疗法治疗(包括西妥昔单抗的靶向治疗)后,进行肿瘤穿刺活检。在获得的肿瘤样品中,通过检测生长因子VEGF-A和TGF-β的水平,计算出VEGF-A /TGF-β的比例。当该比值≥0.850时,可预测西妥昔单抗治疗的高效率。如果其值≤0.384,则预测西妥昔单抗治疗的有效性较低。所述间隔之间的值被认为是不确定的。效果:该方法通过检查肿瘤中生长因子VEGF-A和TGF-β的含量,确定西妥昔单抗靶向治疗在鳞状细胞和口腔粘膜患者中的有效性化疗后第二阶段的组织中包含西妥昔单抗的组织;; 1 cl,2 ex

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号